COPENHAGEN, Jan 30 (Reuters) - Denmark’s Novo Nordisk edged its financial guidance for 2014 higher, saying it now expects sales to grow by 8-11 percent and operating profit to grow by around 10 percent in local currencies.
In October the insulin producer said it expected high single-digit growth in sales and operating profit in 2014 in local currencies.
Operating profit fell to 7.35 billion Danish crowns ($1.34 billion) in the fourth quarter, missing forecasts in a Reuters poll.
Novo’s board proposed a dividend of 4.5 crowns per share and a 12-month share buyback programme of up to 15 billion crowns.
$1 = 5.4691 Danish crowns Reporting by Teis Jensen and Shida Chayesteh; Editing by John Stonestreet